Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
暂无分享,去创建一个
M. Mota | M. Veldhoen | R. Ribeiro | Luísa Canto e Castro | Ângela Afonso | B. Silva-Santos | I. Domingues | I. Toader | P. Napoleão | Rita Ribeiro | M. D. de Sousa | Germano de Sousa | José Germano Rego de Sousa | A. Gomes | M. Serrano | A. Lopes | J. Fanczal | A. Pereira | Claudia Silva | Maria José Rego de Sousa
[1] M. Mota,et al. Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal , 2021, Emerging infectious diseases.
[2] P. Weihe,et al. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands , 2021, Open forum infectious diseases.
[3] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[4] M. van Boven,et al. Controlling the pandemic during the SARS-CoV-2 vaccination rollout , 2021, Nature Communications.
[5] C. Donnelly,et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England , 2021, medRxiv.
[6] Yongsheng Wu,et al. Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study , 2021, The Lancet Microbe.
[7] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[8] M. Veldhoen,et al. Endemic SARS-CoV-2 will maintain post-pandemic immunity , 2021, Nature Reviews Immunology.
[9] M. Veldhoen,et al. Academic labs supporting COVID‐19 diagnostics , 2021, European journal of immunology.
[10] M. V. van Zelm,et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence , 2020, Science Immunology.
[11] S. Lee,et al. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection , 2020, Emerging infectious diseases.
[12] M. Hernán,et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study , 2020, BMJ.
[13] J. Weitz,et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies , 2020, medRxiv.
[14] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.
[15] M. Dake,et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity , 2020, Immunity.
[16] P. G. Choe,et al. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection , 2020, Emerging infectious diseases.
[17] A. Iafrate,et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.
[18] B. Horta,et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys , 2020, The Lancet Global Health.
[19] G. Rodger,et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.
[20] M. Veldhoen,et al. Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset , 2020, medRxiv.
[21] P. Weihe,et al. Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands , 2020, Emerging infectious diseases.
[22] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[23] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[24] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[25] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[26] F. Yu,et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset , 2020, European Respiratory Journal.
[27] J. Ioannidis,et al. The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.
[28] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[29] Kaijun Jiang,et al. SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.
[30] Kyoung-Ho Song,et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.
[31] G. Gao,et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.
[32] Z. Memish,et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Yuxian He,et al. Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients , 2011, Scandinavian journal of infectious diseases.
[34] Wei Liu,et al. Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.
[35] S. Reed. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E‐related strains , 2005, Journal of medical virology.
[36] P. Hsueh,et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.
[37] K L Jackson,et al. Confidence intervals for weighted proportions. , 1994, Statistics in medicine.
[38] D. Tyrrell,et al. The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.
[39] K. Callow. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection , 1985, Journal of Hygiene.
[40] D. Tyrrell,et al. Effects of a "new" human respiratory virus in volunteers. , 1967, British medical journal.
[41] S. Tribler,et al. Prevalence of SARS-CoV-2 antibodies in Denmark 2020: results from nationwide, population-based sero-epidemiological surveys , 2021 .
[42] B. Gladen,et al. Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.